logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Xoma: The Considered Dead is Alive and Kicking. Gilead is Way Undervalued

The Diagnosed Dead Is Far from Dying Xoma (XOMA) : Stock rallied following report announcing an upfront payment from  Novartis , which multiplied the firm’s revenues 10 times over 2014. Novartis paid Xoma $37 million, Novo Nordisk paid $5 million...

Read More

March 11, 2016

0

A Quick Opinion on the CRISPR Patenting Story. Gillead's Improvement of HIV Treatment

About the CRISPR/Cas9 Gene Editing Patent Shareholders of biotechnology firms specialized in CRISPR gene editing technology are in a state of confusion regarding the technology's patents. The confusion is caused by the U.S. Patent and Trademark Office (USPTO) decision to...

Read More

February 17, 2017

0

Jazz Pharmaceuticals: The Expected Good News on March 31, 2016

Of the Upcoming Game-Changing Actions THE EXPECTED FDA APPROVAL OF JAZZ DRUG DEFIBROTIDE On March 31,  the   FDA is expected to decide on the approval of  Jazz Pharmaceuticals’ (JAZZ)   drug  defibrotide.  The drug is for patients with hepatic...

Read More

March 10, 2016

0

Exelixis: Speeding Towards Becoming a Top-Tier Biopharmaceutical

Watching the outperformance of the new approaches for cancer immunotherapies, especially the checkpoint inhibitors and other immunotherapy successful attempts, oncologists recognized that the ultimate efficacy of empowering the immune system to fight cancer will be reached when immunotherapy products are...

Read More

February 21, 2017

0

Academic Researchers Improve on CAR-T Immunotherapy. Guess Who the Beneficiaries Are?

Making Sure that CAR-T Therapy for Cancer Succeeds Academic Researchers Identify a New Process to Raise Natural Armies of Cancer-Targeting T Lymphocytes Outside the Body Unleashing More Power to the Immune System to Fight All Types of Cancers GOOD NEWS...

Read More

February 23, 2017

0

Illumina: A Great Transformation and Transition

As we kept describing it,   Illumina’s (ILMN) is the engine behind the   biological revolution reflected in the current existence of treatments, which aim at targets that were unknown before this firm enabled discovering them. Illumina’s establishing and launching...

Read More

March 8, 2016

0

Immune Design: Encouraging News About Treating Allergic Diseases

Preparing a Prohost Letter dedicated to immunotherapy and the firms that are behind the promising novel approaches towards enabling the immune system to treat, or cure diseases if possible, we fell on other genius approaches. In recent Prohost Letters, we...

Read More

March 4, 2016

0

Incyte: A Thoughtful Research and Collaboration Agreement with Abramson Cancer Center

Incyte Announces a Multi-year Research Collaboration with the Abramson Cancer Center at the University of Pennsylvania . The aim of the agreement with Abramson Cancer Center at the University of Pennsylvania as Incyte (INCY) stated in the press release is...

Read More

February 24, 2017

0

Baxalta Revolutionizes Its Pipeline with Immunotherapy Products

Baxalta (BXLT)   and Precision BioSciences a genome editing company announced a global collaboration to develop a broad series of  allogeneic chimeric antigen receptor (CAR) T  cell therapies directed towards areas of major unmet need in multiple cancers. CAR T...

Read More

February 26, 2016

0

Breakthrough Drugs of the Week

Recent Breakthrough Designated Products CANCER Acute Myeloid Leukemia PKC412 (midostaurin) developed by  Novartis AG (NVS)  is an oral, multi-targeted kinase inhibitor for acute myeloid leukemia (AML) with FLT3 mutations . It is also being studied for aggressive  systemic mastocytosis/mast cell...

Read More

February 23, 2016

0

  • Previous
  • 1
  • 2
  • ...
  • 10
  • 11
  • 12
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy